BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 31, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 7/28 cls
Actelion (SWX:ATLN) Lehman Philippa Gardner Other Overweight 8% CHF 150.4
Gardner increased her estimates after ATLN announced that 2Q06 sales of pulmonary arterial hypertension (PAH) drug Tracleer bosentan rose 52% to CHF216.5M ($175.4M) from CHF142.5M in 2Q05. She increased her FY06 and FY07 revenue estimates to CHF925M from CHF891M and to CHF1.05B from CHF1B. She also increased her FY06 and FY07 EPS estimates to CHF8.54 from CHF7.52 and to CHF9.31 from CHF8.23.
Applied Biosystems Cowen Eric Schmidt Other Neutral 2% $32.83
(ABI) Piper Jaffray Edward Tenthoff Downgrade Market perform (from market outperform)
Schmidt raised his fiscal 07 and fiscal 08 revenue estimates to $2.04B from $2.01B and to $2.16B from $2.12B after the company reported fiscal 06 non-GAAP EPS of $1.24, up 17% from $1.06 in the same period last year.
Tenthoff lowered his FY07 revenue estimate to $2.06B from $2.07B on the earnings news.
Biogen Idec (BIIB) Baird Christopher Raymond

Read the full 1027 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >